Common Genetic Variants in 53BP1 Associated with Nonsmall-cell Lung Cancer Risk in Han Chinese

Archives of Medical Research

Volumn 45, Issue 1, 2014, Pages 84-89

  Zhang, Haibo ^a,b   Hao, Shanhu ^b   Zhao, Junhua ^a   Zhou, Baosen ^a   Ren, Yangwu ^a   Yan, Ying ^b   Zhao, Yuxia ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

53BP1; Disease susceptibility; Lung cancer; Single nucleotide polymorphism; TP53

Indexed keywords

P53 BINDING PROTEIN 1; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC VARIABILITY; GENOTYPE; HUMAN; LUNG CARCINOGENESIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

53BP1; DISEASE SUSCEPTIBILITY; LUNG CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; TP53;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LINKAGE DISEQUILIBRIUM; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84892505329     PISSN: 01884409     EISSN: 18735487     Source Type: Journal    
DOI: 10.1016/j.arcmed.2013.10.011     Document Type: Article

References (24)

1. McKay J.D., Hung R.J., Gaborieau V., et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet 2008, 40:1404-1406.
2. Wang Y., Broderick P., Webb E., et al. Common 5p15.33 and 6p21.33 variants influence lung cancer risk. Nat Genet 2008, 40:1407-1409.
3. Amos C.I., Wu X., Broderick P., et al. Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet 2008, 40:616-622.
4. Hu Z., Wu C., Shi Y., et al. A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. Nat Genet 2011, 43:792-796.
5. Kiyohara C., Horiuchi T., Miyake Y., et al. Cigarette smoking, TP53 Arg72-Pro, 53BP1 Asp353Glu and the risk of lung cancer in a Japanese population. Oncol Rep 2010, 23:1361-1368.
6. Rudd M.F., Webb E.L., Matakidou A., et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006, 16:693-701.
7. Truong T., Sauter W., McKay J.D., et al. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. Carcinogenesis 2010, 31:625-633.
8. Iwabuchi K., Bartel P.L., Li B., et al. Two cellular proteins that bind to wild-type but not mutant p53. Proc Natl Acad Sci USA 1994, 91:6098-6102.
9. Sancar A., Lindsey-Boltz L.A., Unsal-Kacmaz K., et al. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004, 73:39-85.
10. Ma H., Hu Z., Zhai X., et al. Joint effects of single nucleotide polymorphisms in P53BP1 and p53 on breast cancer risk in a Chinese population. Carcinogenesis 2006, 27:766-771.
11. Cao Y.Y., Ge H., Chen L.Q., et al. Correlation of 53BP1 and p53 polymorphisms to susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma. Ai Zheng 2007, 26:1052-1057.
12. Rafnar T., Sulem P., Besenbacher S., et al. Genome-wide significant association between a sequence variant at 15q15.2 and lung cancer risk. Cancer Res 2011, 71:1356-1361.
13. Chen K., Hu Z., Wang L.E., et al. Polymorphic 53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:4300-4305.
14. Dumont P., Leu J.I., Della Pietra A.C., et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003, 33:357-365.
15. Pim D., Banks L. p53 polymorphic variants at codon 72 exert different effects on cell cycle progression. Int J Cancer 2004, 108:196-199.
16. Siddique M., Sabapathy K. Trp53-dependent DNA-repair is affected by the codon 72 polymorphism. Oncogene 2006, 25:3489-3500.
17. Iwabuchi K., Li B., Massa H.F., et al. Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2. J Biol Chem 1998, 273:26061-26068.
18. Rothman K. Measuring Interaction 2002, Oxford University Press, New York.
19. Jiang D., Yao L., Wang W., et al. TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis. World J Gastroenterol 2011, 17:1227-1233.
20. Dahabreh I., Linardou H., Bouzika P., et al. TP53 Arg72Pro polymorphism and colorectal cancer risk: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 2010, 19:1840-1847.
21. Cai X., Yang M. The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis. J Cancer Res Clin Oncol 2012, 138:555-561.
22. Bond G.L., Hu W., Bond E.E., et al. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 2004, 119:591-602.
23. Mechanic L., Marrogi A., Welsh J., et al. Polymorphisms in XPD and TP53 and mutation in human lung cancer. Carcinogenesis 2005, 26:597-604.
24. Gorgoulis V.G., Vassiliou L.V., Karakaidos P., et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005, 434:907-913.